Geode Capital Management LLC Buys 25,970 Shares of COMPASS Pathways plc (NASDAQ:CMPS)

Geode Capital Management LLC increased its stake in COMPASS Pathways plc (NASDAQ:CMPS) by 160.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 42,169 shares of the company’s stock after buying an additional 25,970 shares during the period. Geode Capital Management LLC owned 0.06% of COMPASS Pathways worth $266,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the stock. Y Intercept Hong Kong Ltd bought a new position in COMPASS Pathways in the third quarter worth about $131,000. Point72 Asset Management L.P. bought a new position in COMPASS Pathways in the third quarter worth about $371,000. Polar Asset Management Partners Inc. raised its stake in COMPASS Pathways by 83.3% in the third quarter. Polar Asset Management Partners Inc. now owns 567,600 shares of the company’s stock worth $3,576,000 after buying an additional 258,000 shares in the last quarter. Sio Capital Management LLC raised its stake in COMPASS Pathways by 211.7% in the third quarter. Sio Capital Management LLC now owns 914,639 shares of the company’s stock worth $5,762,000 after buying an additional 621,222 shares in the last quarter. Finally, Walleye Capital LLC bought a new position in shares of COMPASS Pathways during the third quarter valued at approximately $2,126,000. 46.19% of the stock is owned by institutional investors.

COMPASS Pathways Trading Down 4.5 %

NASDAQ:CMPS opened at $3.37 on Tuesday. The company’s 50 day moving average price is $4.41 and its 200-day moving average price is $5.92. COMPASS Pathways plc has a 52 week low of $3.16 and a 52 week high of $12.75. The company has a quick ratio of 8.91, a current ratio of 8.91 and a debt-to-equity ratio of 0.15. The stock has a market cap of $230.58 million, a price-to-earnings ratio of -1.53 and a beta of 2.27.

COMPASS Pathways (NASDAQ:CMPS) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.56) EPS for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.04. During the same quarter in the previous year, the firm posted ($0.67) EPS. On average, equities research analysts forecast that COMPASS Pathways plc will post -2.33 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have weighed in on CMPS shares. Royal Bank of Canada decreased their target price on shares of COMPASS Pathways from $23.00 to $18.00 and set an “outperform” rating for the company in a research note on Friday, November 1st. HC Wainwright decreased their target price on shares of COMPASS Pathways from $120.00 to $60.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Finally, Maxim Group decreased their target price on shares of COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $33.60.

COMPASS Pathways Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.